GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » EV-to-EBITDA

Vivos Therapeutics (Vivos Therapeutics) EV-to-EBITDA : -0.41 (As of May. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vivos Therapeutics's enterprise value is $6.85 Mil. Vivos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.67 Mil. Therefore, Vivos Therapeutics's EV-to-EBITDA for today is -0.41.

The historical rank and industry rank for Vivos Therapeutics's EV-to-EBITDA or its related term are showing as below:

VVOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.4   Med: -0.8   Max: -0.15
Current: -0.41

During the past 6 years, the highest EV-to-EBITDA of Vivos Therapeutics was -0.15. The lowest was -21.40. And the median was -0.80.

VVOS's EV-to-EBITDA is ranked worse than
100% of 488 companies
in the Medical Devices & Instruments industry
Industry Median: 16.1 vs VVOS: -0.41

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Vivos Therapeutics's stock price is $2.13. Vivos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.050. Therefore, Vivos Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Vivos Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Vivos Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics EV-to-EBITDA Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -8.07 -1.50 -0.33 -1.39

Vivos Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.24 -0.67 -0.37 -1.39

Competitive Comparison of Vivos Therapeutics's EV-to-EBITDA

For the Medical Devices subindustry, Vivos Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos Therapeutics's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vivos Therapeutics's EV-to-EBITDA falls into.



Vivos Therapeutics EV-to-EBITDA Calculation

Vivos Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6.853/-16.673
=-0.41

Vivos Therapeutics's current Enterprise Value is $6.85 Mil.
Vivos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivos Therapeutics  (NAS:VVOS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vivos Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.13/-11.050
=At Loss

Vivos Therapeutics's share price for today is $2.13.
Vivos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.050.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Vivos Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Therapeutics (Vivos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Executives
Ronald Kirk Huntsman director, 10 percent owner, officer: Chairman & CEO 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman officer: Chief Financial Officer 6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow director REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson director 2 MUSICK, IRVINE CA 92618
Anja B Krammer director C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh director, 10 percent owner, officer: Chief Medical Officer 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129